<DOC>
	<DOCNO>NCT01685151</DOCNO>
	<brief_summary>To evaluate efficacy safety day ramelteon tablet sublingual administration ( TAK-375SL ) maintenance treatment bipolar 1 disorder .</brief_summary>
	<brief_title>A Safety Efficacy Study Ramelteon Tablets Sublingual Administration ( TAK-375SL ) Maintenance Treatment Bipolar 1 Disorder</brief_title>
	<detailed_description>The drug test study call Ramelteon . Ramelteon test treat people Bipolar 1 Disorder . This study look symptom bipolar disorder people take Ramelteon . The study enroll approximately 495 patient . Participants randomly assign ( chance , like flip coin ) one three treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Ramelteon ( Dose 1 ) - Ramelteon ( Dose 2 ) - Placebo ( dummy inactive pill ) - tablet look like study drug active ingredient All participants ask take one tablet every night bedtime throughout study . This multi-centre trial conduct North America Europe . The overall time participate study 13 month . Participants make 17 visit clinic , contact telephone 30 day last dose study drug follow-up assessment . This 12-month study design evaluate efficacy TAK-375SL maintenance treatment bipolar 1 disorder . At time , Takeda decide withdraw study business reason . No participant enrol study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>1 . In opinion investigator , subject capable understanding comply protocol requirement . 2 . The subject legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . The subject suffers bipolar 1 disorder , accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion confirm Structured Clinical Interview DSM Disorders ( SCID ) . 4 . The subject man woman age 18 75 year , inclusive . 5 . The subject identify caregiver person responsible ( eg . Family member , spouse , case worker nurse residential living facility ) consider reliable investigator . 6 . The recent mood episode ( depression , mania , mixed episode , hypomania ) 8 week 9 month prior screen . 7 . The subject stable opinion PI least 8 week prior baseline recent mood episode . 8 . The subject MADRS total score ≤12 Screening Baseline visit . 9 . The subject YMRS score ≤10 Screening Baseline visit . 10 . The subject CGIS score ≤2 Screening Baseline visit . 11 . HAMA score ≤21 Screening Baseline visit . 12 . The subject 's medication bipolar 1 disorder stable ie , change psychotropic medication dose adjustment psychotropic medication bipolar 1 disorder make least 8 week prior randomization . 13 . A male subject nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 30 day last dose . 14 . A female subject childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study 30 day last dose . 1 . The subject receive investigational compound &lt; 30 day Screening 5 halflives prior Screening , whichever longer . 2 . The subject ever receive TAK375 TAK375 SL previous clinical study ever use ramelteon . 3 . The subject immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . The subject one following : 1 . Any current psychiatric disorder primary focus treatment bipolar 1 disorder define DSMIVTR , assess SCID . 2 . Current history : schizophrenia psychotic disorder , include schizoaffective disorder , major depression psychotic feature , bipolar depression psychotic feature ( exception psychosis associate manic mixed episode ) , OCD , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIVTR . 3 . Current diagnosis history alcohol substance abuse ( exclude nicotine caffeine ) define DSMIVTR full sustain remission least three month day screen ( Subject must also negative urine drug screen Screening Baseline ; exception benzodiazepine opiates provided subject valid prescription ) . 4 . Current diagnosis history alcohol substance dependence ( exclude nicotine caffeine ) define DSMIVTR full sustain remission least three month day screen . ( Subject must also negative urine drug screen Screening Baseline ; exception benzodiazepine opiates provided subject valid prescription ) . 5 . Presence history clinically significant neurological disorder ( include epilepsy ) determine investigator . 6 . Neurodegenerative disorder ( Alzheimer disease , Parkinson disease , multiple sclerosis , Huntington disease , etc ) . 7 . Any Axis II disorder might compromise study . 8 . History Rapid Cycling Bipolar Disorder : Subjects 8 episode mood disorder per year . The episode must meet duration symptom criterion Major Depressive , Manic , Mixed , Hypomanic episode must demarcate either period full remission switch episode opposite polarity . Manic , Hypomanic , Mixed Episodes count pole . Each mood episode must confirm appropriate patient history formal diagnosis medical practitioner . 5 . The subject experience first episode mood disorder age 55 year . 6 . The subject medication antidepressant ( except fluvoxamine ) , mood stabilizer ( lithium , valproate , lamotrigine ) , atypical antipsychotic ( risperidone , olanzapine , quetiapine , ziprasidone , aripiprazole , ) bipolar 1 disorder . If subject lithium and/or valproate , level specify range : lithium ( serum level 1.2 mEq/L ) ; valproate ( serum level 125 mcg/ml ) screening . If subject psychotropic medication , investigator discretion , withdrawal medication allow two week prior baseline visit . 7 . The subject medication take antidepressant medication ( take medication commonly use standard treatment bipolar I disorder , benzodiazepine ) . 8 . The subject receive electroconvulsive therapy , vagal nerve stimulation , repetitive transcranial magnetic stimulation within 6 month prior Screening . 9 . The subject start receive formal cognitive behavioral therapy , systematic psychotherapy within 30 day screen plan initiate therapy study ( supportive therapy , marital therapy bereavement counsel allow ) . 10 . The subject significant risk suicide accord investigator 's clinical judgment score ≥5 item 10 ( suicidal thought ) MADRS make suicide attempt previous 6 month . 11 . The subject require take excluded medication anticipate subject require treatment least 1 disallow concomitant medication study . 12 . The subject clinically significant unstable illness , example hepatic impairment renal insufficiency , cardiovascular , pulmonary , gastrointestinal , endocrine , neurological , rheumatologic , immunologic , hematological , infectious , dermatological disorder metabolic disturbance . 13 . The subject history current diagnosis Fibromyalgia , Chronic Fatigue Syndrome , Chronic Pain Syndrome Sleep apnea ( central and/or obstructive ) . If obstructive sleep apnea correct surgically , polysomnogram show normal apneahypopnea index require . 14 . The subject previous history cancer remission le 5 year prior first dose study medication . This criterion include subject basal cell stage I squamous cell carcinoma skin . 15 . The subject 1 laboratory value outside normal range , base blood urine sample take Screening Visit , consider investigator clinically significant ; subject follow value Screening Visit : 1 . A serum creatinine value &gt; 1.5 time upper limit normal ( xULN ) . 2 . A serum total bilirubin value &gt; 1.5 xULN . 3 . A serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value &gt; 2 xULN . 16 . The subject glycosylated hemoglobin ( HbA1C ) ≥7 % screen prior diagnosis diabetes and/or treatment diabetes . NOTE : Subjects know diabetes exclude . 17 . The subject thyroid stimulate hormone ( TSH ) value outside normal range Screening Visit deem clinically significant investigator . NOTE : Free T4 check TSH range . If free T4 abnormal subject exclude . 18 . Positive Hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( HCV ) antibody , history Human immunodeficiency virus ( HIV ) infection 19 . If male , subject intend donate sperm course study 12 week thereafter . If female , subject pregnant lactating intend become pregnant , , within 30 day participate study ; intend donate ova time period . 20 . The subject clinically significant abnormal vital sign determine investigator . 21 . The subject abnormal electrocardiogram ( ECG ) determine central reader confirm clinically significant investigator . 22 . The subject disease take medication , opinion investigator , could interfere assessment safety , tolerability , efficacy . 23 . The subject positive urine drug screen . NOTE : Positive urine drug screen benzodiazepine opiate subject valid prescription allow . 24 . The subject , opinion investigator , unlikely comply clinical study protocol unsuitable reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>